14. A chemically stable compressed tablet free of lactose which comprises about 1% to about 50% by weight of an optically pure enantiomer or a pharmaceutically acceptable salt thereof, and about 99% to about 50% by weight of at least one pharmaceutically acceptable excipient, wherein said tablet does not dissolve in less than three minutes when subjected to the DISSOLUTION TEST.

17. The compressed tablet of claim 13 or 14, wherein said fluoxetine is present in an amount from about 1 mg to about 200 mg.

18. The compressed tablet of claim 17, wherein said fluoxetine is present in an amount of about 2 mg to about 100 mg.

19. The compressed tablet of claim 13 or 14, wherein said fluoxetine enantiomer is optically pure (R)-fluoxetine.

20. The compressed tablet of claim 13 or 14, wherein said fluoxetine enantiomer is optically pure (S)-fluoxetine.

22. The compressed tablet of claim 13 or 14, wherein said compressed tablet is sterile, anhydrous and non-hygroscopic.

29. The composition or tablet of claim 1, 13, 14, 21, 23, or 24 wherein said pharmaceutically acceptable salt is a hydrochloride salt.

30. A stable pharmaceutical unit dosage form which comprises an optically pure enantiomer of fluoxetine, or a pharmaceutically acceptable salt thereof, and one of more pharmaceutically acceptable excipients wherein said dosage form is not a capsule or gel cap and does not dissolve in less than three minutes when subjected to the DISSOLUTION TEST.